Out-licensing: Diagnostic/Antibody-based diagnostics & Gastrointestinal

Latest: Watch here for details of new products and services.

About Us: Pharmalicensing - Open Innovation for the life sciences
Our Products: Overview; Partnering Search; Company Profiling; Partneringtools; Reports; Partnering Consulting; Due Diligence; Comparison
Due Diligence: Overview; Top Applications; Online Panel Discussions; Request Consultation
Case Studies: See what others think about our service
Newsletter: Partnering update; Key reports; Subscribe
Quick Links: Profile now; Register now; Profiled companies; Featured events; Industry news; PR Newswire; Jobs; Forums
Contact Pharmalicensing: Send an email; Call us: +44 1904 520460; Request a callback
RSS Feeds: Keep up to date

Pharmalicensing Ltd
is a division of

Up-to-date access to technology licensing opportunities worldwide.

Displaying 1..3 of 3 - per page
Order by

Novel target and monoclonal antibody for early diagnosis and/or therapeutic intervention More

Recently characterized MUC17 gene highly specific for pancreatic cancer. More

Diagnostic and potential therapeutic applications for mucin gene 4 (MUC4). More

Displaying 1..3 of 3 - per page
Order by

Therapeutic target: Appendicitis; Cholangitis, sclerosing; Colitis; Colitis, ulcerative; Constipation; Crohn's disease; Diarrhea; Dyspepsia; Electrolyte replacement; Emesis; Emesis, motion; Esophagitis; Flatulence; Food poisoning; Gastritis; Gastroesophageal reflux disorder; Gastrointestinal (other); Gastrointestinal secretions; Gastroprokinetic; Helicobacter pylori; Inflammatory bowel disease; Irritable bowel syndrome; Nausea; Pancreatitis; Ulcer; Ulcer, gastric; Ulcer, gastroduodenal; Ulcer, peptic
Development phase: Early Stage; Preclinical; Phase I; Phase I/II; Phase II; Phase III; Phase III/IV; Preregistration; Registered

Industry news: Pharmalicensing provides comprehensive industry coverage.